TEBIO-TECHNE Corp company profile
$72.80−0.05%Close 13 Nov 2026
About BIO-TECHNE Corp
Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. It operates two segments. Protein Sciences, which represents approximately 72% of net sales in fiscal 2026, supplies biological reagents, proteomic analytical tools and immunoassays to academic researchers, pharmaceutical and biotech companies, and contract research organizations. Diagnostics and Spatial Biology, representing approximately 28% of net revenues, provides diagnostic controls, calibrators and assays, spatial biology instruments and in-situ hybridization assays, and genetic and oncology kits. The company sells directly and through distributors and OEM agreements, primarily in North America, Europe and China, and manufactures most of its products in North America, the U.K., Canada, Switzerland and China.
A summary of the business section of the company's latest annual report, filed 24 Aug 2026.
Company facts
| Ticker | TECH · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 30 June |
|---|
| Reporting currency | USD |
|---|
| CIK | 842023 |
|---|
| Latest annual report | 10-K, filed 24 Aug 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| James Hippel | CFO | 589K · 0.4% | Option exercise, 15 Aug 2026 |
|---|
| Kim Kelderman | Chief Executive Officer · Director | 378K · 0.2% | Option exercise, 15 Aug 2026 |
|---|
| John L. Higgins | Director | 129K · 0.1% | Option exercise, 28 Sep 2026 |
|---|
| Robert V. Baumgartner | Director | 108K · 0.1% | Option exercise, 22 Sep 2026 |
|---|
| Roeland Nusse, Ph.D. | Director | 108K · 0.1% | Option exercise, 25 Aug 2025 |
|---|
| William Geist | PRESIDENT, PROTEIN SCIENCES | 69.6K · 0% | Option exercise, 15 Aug 2026 |
|---|
| Joseph Keegan, Ph.D. | Director | 61.4K · 0% | Grant or award, 30 Oct 2025 |
|---|
| Shane Bohnen | SVP - General Counsel | 41.8K · 0% | Shares withheld for tax, 15 Aug 2026 |
|---|
| Alpna Seth, Ph.D. | Director | 41.3K · 0% | Grant or award, 30 Oct 2025 |
|---|
| Dr. Rupert Vessey, MA, BM BCh, FRCP, DPhil | Director | 39.2K · 0% | Grant or award, 30 Oct 2025 |
|---|
| Julie L. Bushman | Director | 28.0K · 0% | Grant or award, 30 Oct 2025 |
|---|
| Matthew McManus | President - Diag & Spatial Bio | 14.0K · 0% | Option exercise, 1 Feb 2026 |
|---|
| Dr. Judith Klimovsky | Director | 7.3K · 0% | Grant or award, 30 Oct 2025 |
|---|
| Dr. Amy Herr | Director | 1.3K · 0% | Option exercise, 15 Aug 2026 |
|---|
| Crouse Steven C. | President - Diag & Spatial Bi | — | Shares withheld for tax, 15 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
TECH in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.